Patient Retention Ads Should Be Larger Part Of DTC Spend, Consultant Says
Pharmaceutical companies should devote more of their advertising budgets to patient retention and compliance, DTC Perspectives CEO Robert Ehrlich said
You may also be interested in...
Although FDA is issuing fewer warning letters, those issued are more likely to signal a potential enforcement action, FDA Associate Commissioner Peter Pitts suggested during the DTC National Conference & Expo in Boston March 30
The impact of FDA's draft guidance on disease awareness ads will depend upon how willing manufacturers are to allot portions of their advertising budgets to non-branded ads
Pharmaceutical companies should devote more of their advertising budgets to collective disease education efforts, Rx Insight CEO Bob Ehrlich said